<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207151</article-id><article-id pub-id-type="doi">10.1101/2025.07.08.663653</article-id><article-id pub-id-type="archive">PPR1047688</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lombardi</surname><given-names>Pasquale</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ramon-Gil</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="fn" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Brunetti</surname><given-names>Leonardo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Manfredi</surname><given-names>Giulia Francesca</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Merces</surname><given-names>George</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fulgenzi</surname><given-names>Claudia Angela Maria</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>D’Alessio</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Torkpour</surname><given-names>Aria</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Celsa</surname><given-names>Ciro</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Stefanini</surname><given-names>Bernardo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Crowley</surname><given-names>Fionnuala</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Marron</surname><given-names>Thomas U.</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Saeed</surname><given-names>Anwaar</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Pinter</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Scheiner</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yi-Hsiang</given-names></name><xref ref-type="aff" rid="A12">12</xref><xref ref-type="aff" rid="A13">13</xref><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Pei-Chang</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Nishida</surname><given-names>Naoshi</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ryan Po-Ting</given-names></name><xref ref-type="aff" rid="A16">16</xref></contrib><contrib contrib-type="author"><name><surname>Dalbeni</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="A17">17</xref></contrib><contrib contrib-type="author"><name><surname>Vivaldi</surname><given-names>Caterina</given-names></name><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Masi</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="A18">18</xref></contrib><contrib contrib-type="author"><name><surname>Rohlen</surname><given-names>Natascha</given-names></name><xref ref-type="aff" rid="A19">19</xref></contrib><contrib contrib-type="author"><name><surname>Felden</surname><given-names>Johann von</given-names></name><xref ref-type="aff" rid="A20">20</xref></contrib><contrib contrib-type="author"><name><surname>Kaseb</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="A21">21</xref></contrib><contrib contrib-type="author"><name><surname>Galle</surname><given-names>Peter R.</given-names></name><xref ref-type="aff" rid="A22">22</xref></contrib><contrib contrib-type="author"><name><surname>Kudo</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Wei-Fan</given-names></name><xref ref-type="aff" rid="A23">23</xref></contrib><contrib contrib-type="author"><name><surname>Rimassa</surname><given-names>Lorenza</given-names></name><xref ref-type="aff" rid="A24">24</xref><xref ref-type="aff" rid="A25">25</xref></contrib><contrib contrib-type="author"><name><surname>Parisi</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="A26">26</xref></contrib><contrib contrib-type="author"><name><surname>Kelley</surname><given-names>Robin Kate</given-names></name><xref ref-type="aff" rid="A27">27</xref></contrib><contrib contrib-type="author"><name><surname>Toyoda</surname><given-names>Hidenori</given-names></name><xref ref-type="aff" rid="A28">28</xref></contrib><contrib contrib-type="author"><name><surname>Pirisi</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Jabar</surname><given-names>Rahim Falah</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A31">31</xref></contrib><contrib contrib-type="author"><name><surname>Rakaee</surname><given-names>Mehrdad</given-names></name><xref ref-type="aff" rid="A29">29</xref><xref ref-type="aff" rid="A30">30</xref><xref ref-type="aff" rid="A31">31</xref><xref ref-type="aff" rid="A32">32</xref></contrib><contrib contrib-type="author"><name><surname>Cabibbo</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A33">33</xref></contrib><contrib contrib-type="author"><name><surname>Cammà</surname><given-names>Calogero</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Piscaglia</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A34">34</xref></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Sohyun</given-names></name><xref ref-type="aff" rid="A35">35</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Dong Jun</given-names></name><xref ref-type="aff" rid="A36">36</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A37">37</xref></contrib><contrib contrib-type="author"><name><surname>Daniele</surname><given-names>Gennaro</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mann</surname><given-names>Derek A.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chon</surname><given-names>Hong Jae</given-names></name><xref ref-type="aff" rid="A8">8</xref><xref ref-type="fn" rid="FN2">#</xref></contrib><contrib contrib-type="author"><name><surname>Leslie</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A38">38</xref><xref ref-type="fn" rid="FN2">#</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pinato</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="fn" rid="FN2">#</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Surgery &amp; Cancer, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, Hammersmith Hospital, <addr-line>Du Cane Road</addr-line>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>Phase 1 Unit, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rg70c39</institution-id><institution>Fondazione Policlinico Universitario A. Gemelli</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>IRCCS</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03h7r5v07</institution-id><institution>Università Cattolica del Sacro Cuore</institution></institution-wrap>, <city>Rome</city>, <country country="IT">Italy</country></aff><aff id="A3"><label>3</label>The Newcastle University Centre for Cancer, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle Upon Tyne</city>, <country country="GB">U.K</country></aff><aff id="A4"><label>4</label>Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy</aff><aff id="A5"><label>5</label>Image Analysis Unit, Faculty of Medical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle upon Tyne</city>, <country country="GB">UK</country></aff><aff id="A6"><label>6</label>Section of Gastroenterology &amp; Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/044k9ta02</institution-id><institution>University of Palermo</institution></institution-wrap>, <city>Palermo</city>, <country country="IT">Italy</country></aff><aff id="A7"><label>7</label>Department of Medical and Surgical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01111rn36</institution-id><institution>University of Bologna</institution></institution-wrap>, <country country="IT">Italy</country></aff><aff id="A8"><label>8</label>Medical Oncology, Department of Internal Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/000bmd763</institution-id><institution>CHA Bundang Medical Center</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04yka3j04</institution-id><institution>CHA University</institution></institution-wrap>, <city>Seongnam</city>, <country country="KR">Republic of Korea</country></aff><aff id="A9"><label>9</label>Department of Medicine, Division of Hematology/Oncology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0317dzj93</institution-id><institution>Tisch Cancer Institute</institution></institution-wrap>, Mount Sinai Hospital, <city>New York</city>, <state>NY</state>, <country country="US">USA</country></aff><aff id="A10"><label>10</label>Department of Medicine, Division of Hematology &amp; Oncology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ehecz88</institution-id><institution>University of Pittsburgh Medical Center</institution></institution-wrap>, <city>Pittsburgh</city>, <state>PA</state>, <country country="US">USA</country></aff><aff id="A11"><label>11</label>Division of Gastroenterology and Hepatology, Department of Medicine III, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05n3x4p02</institution-id><institution>Medical University of Vienna</institution></institution-wrap>, <city>Vienna</city>, <country country="AT">Austria</country></aff><aff id="A12"><label>12</label>Department of Medical Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ymy8z76</institution-id><institution>Taipei Veterans General Hospital</institution></institution-wrap>, <city>Taipei</city>, <country country="TW">Taiwan</country></aff><aff id="A13"><label>13</label>Division of Gastroenterology and Hepatology, Department of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ymy8z76</institution-id><institution>Taipei Veterans General Hospital</institution></institution-wrap>, <city>Taipei</city>, <country country="TW">Taiwan</country></aff><aff id="A14"><label>14</label>Institute of Clinical Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00se2k293</institution-id><institution>National Yang Ming Chiao Tung University</institution></institution-wrap>, <city>Taipei</city>, <country country="TW">Taiwan</country></aff><aff id="A15"><label>15</label>Department of Gastroenterology and Hepatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kt9ap64</institution-id><institution>Kindai University</institution></institution-wrap> Faculty of Medicine, <city>Osaka</city>, <country country="JP">Japan</country></aff><aff id="A16"><label>16</label>Department of Gastroenterology and Hepatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02verss31</institution-id><institution>Chang Gung Medical Foundation</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02dnn6q67</institution-id><institution>Linkou Chang Gung Memorial Hospital</institution></institution-wrap>, <addr-line>Taiwan NO 5, Fu-Hsing Street</addr-line>, <city>Kuei Shan</city>, <addr-line>Taoyuan 333</addr-line>, <country country="TW">Taiwan</country></aff><aff id="A17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/039bp8j42</institution-id><institution>University of Verona</institution></institution-wrap>, Department of Medicine General Medicine C Unit &amp; Liver Unit</aff><aff id="A18"><label>18</label>Department of Translational Research and New Technologies in Medicine and Surgery, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ad39j10</institution-id><institution>University of Pisa</institution></institution-wrap>, <city>Pisa</city>, <country country="IT">Italy</country>; Unit of Medical Oncology 2, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05xrcj819</institution-id><institution>Azienda Ospedaliero-Universitaria Pisana</institution></institution-wrap>, <city>Pisa</city>, <country country="IT">Italy</country></aff><aff id="A19"><label>19</label>Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Freiburg University Medical Center, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>University of Freiburg</institution></institution-wrap>, <city>Freiburg</city>, <country country="DE">Germany</country></aff><aff id="A20"><label>20</label>Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01zgy1s35</institution-id><institution>University Medical Center Hamburg-Eppendorf</institution></institution-wrap>, <city>Hamburg</city>, <country country="DE">Germany</country></aff><aff id="A21"><label>21</label>Gastrointestinal Medical Oncology Department, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>University of Texas MD Anderson Cancer Center</institution></institution-wrap>, <city>Houston</city>, <state>TX</state></aff><aff id="A22"><label>22</label>University Medical Center Mainz, I. Dept. of Internal Medicine, Mainz, Germany</aff><aff id="A23"><label>23</label>Department of Internal Medicine, Center for Digestive Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0368s4g32</institution-id><institution>China Medical University Hospital</institution></institution-wrap>, <city>Taichung</city>, <country country="TW">Taiwan</country></aff><aff id="A24"><label>24</label>Department of Biomedical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/020dggs04</institution-id><institution>Humanitas University</institution></institution-wrap>, <addr-line>Via Rita Levi Montalcini 4</addr-line>, <postal-code>20072</postal-code><city>Pieve Emanuele, Milan</city>, <country country="IT">Italy</country></aff><aff id="A25"><label>25</label>Medical Oncology and Hematology Unit, Humanitas Cancer Center, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d538656</institution-id><institution>IRCCS Humanitas Research Hospital</institution></institution-wrap>, <addr-line>Via A. Manzoni 56</addr-line>, <postal-code>20089</postal-code><city>Rozzano</city>, <state>Milan</state>, <country country="IT">Italy</country></aff><aff id="A26"><label>26</label>Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy</aff><aff id="A27"><label>27</label>Department of Medicine (Hematology/Oncology), <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05yndxy10</institution-id><institution>UCSF Helen Diller Family Comprehensive Cancer Center</institution></institution-wrap>, <city>San Francisco</city>, <state>California</state>, <country country="US">USA</country></aff><aff id="A28"><label>28</label>Department of Gastroenterology and Hepatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0266t0867</institution-id><institution>Ogaki Municipal Hospital</institution></institution-wrap>, <city>Ogaki</city>, <country country="JP">Japan</country></aff><aff id="A29"><label>29</label>Department of Cancer Genetics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j9c2840</institution-id><institution>Oslo University Hospital</institution></institution-wrap>, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A30"><label>30</label>Department of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Brigham and Women’s Hospital</institution></institution-wrap>, Harvard Medical School, <city>Boston</city>, <state>Massachusetts</state></aff><aff id="A31"><label>31</label>Department of Clinical Pathology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/030v5kp38</institution-id><institution>University Hospital of North Norway</institution></institution-wrap>, <city>Tromsø</city>, <country country="NO">Norway</country></aff><aff id="A32"><label>32</label>Department of Medical Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00wge5k78</institution-id><institution>UiT The Arctic University of Norway</institution></institution-wrap>, <city>Tromsø</city>, <country country="NO">Norway</country></aff><aff id="A33"><label>33</label>Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), <institution-wrap><institution-id institution-id-type="ror">https://ror.org/044k9ta02</institution-id><institution>University of Palermo</institution></institution-wrap>, <country country="IT">Italy</country></aff><aff id="A34"><label>34</label>Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tfzc498</institution-id><institution>IRCCS</institution></institution-wrap> Azienda Ospedaliero-Universitaria di Bologna, <country country="IT">Italy</country></aff><aff id="A35"><label>35</label>Department of Pathology, CHA Bundang Medical Center, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04yka3j04</institution-id><institution>CHA University</institution></institution-wrap> School of Medicine, <city>Seongnam</city>, <country country="KR">Republic of Korea</country></aff><aff id="A36"><label>36</label>Department of Biomedical Science, College of Life Science, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04yka3j04</institution-id><institution>CHA University</institution></institution-wrap> School of Medicine, <city>Seongnam</city>, <country country="KR">Republic of Korea</country></aff><aff id="A37"><label>37</label>Division of Gastroenterology and Hepatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California</institution></institution-wrap>, <city>San Francisco</city>, <state>California</state>, <country country="US">USA</country></aff><aff id="A38"><label>38</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/044m9mw93</institution-id><institution>NIHR, Newcastle Biomedical Research Centre</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kj2bm70</institution-id><institution>Newcastle University</institution></institution-wrap>, <city>Newcastle upon Tyne</city>, Tyne and Wear, <country country="GB">UK</country></aff><author-notes><corresp id="CR1"><bold>Co-Corresponding author:</bold>, Dr David J. Pinato, MD MRes MRCP PhD, Clinical Reader and Consultant in Medical Oncology Imperial College London Hammersmith Campus, Du Cane Road, W12 0HS, London (UK), Tel: +44 0207 5942799; <email>david.pinato@imperial.ac.uk</email>. Dr. Hong Jae Chon, MD, Hong Jae Chon, MD, PhD. Professor, Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea., Tel: +82 31 780 7590; <email>minidoctor@cha.ac.kr</email></corresp><fn id="FN1"><label>*</label><p id="P1">co-first authors</p></fn><fn id="FN2"><label>#</label><p id="P2">co-last senior contributors</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>10</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P3">Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, remains a significant and poorly understood clinical challenge.</p></sec><sec id="S2"><title>Methods</title><p id="P4">We analysed 1296 patients with HCC and Child-Pugh A liver cirrhosis treated with frontline A+B (AB-real) and validated findings in 645 trial participants recruited to IMbrave150 and GO30140. PRef was defined by Society for the Immunotherapy of Cancer (SITC) criteria as progressive disease in the first 6 months after treatment initiation. Patients who achieved complete response, partial response or stable disease for ≥ 6 months were classified as responders. We performed a multi-parametric analysis of pre-treatment tumour tissue including machine learning-based quantification of tumour-infiltrating lymphocytes, imaging mass cytometry and RNA sequencing (RNAseq) to evaluate differences in the tumour microenvironment (TME) of PRef versus responding patients. We employed conditional inference tree analyses to provide a hierarchical organisation of determinants of PRef.</p></sec><sec id="S3"><title>Results</title><p id="P5">Among 677 AB-real and 378 trial patients evaluable by SITC criteria, PRef identified inferior median OS in comparison with responding patients (AB-real: 7.3 vs. 31.5 months, HR 3.7, 95%CI 2.8–8.5, p&lt;0.001; Trials: 10.8 vs. NR, HR 4.6, 95%CI 3.3–6.3, p&lt;0.001). PRef patients exhibited higher baseline systemic inflammation (neutrophil-to-lymphocyte ratio, NLR ≥3), a distinctively immunosuppressive TME enriched in CD163<sup>+</sup> tumour-associated macrophages and a higher T<sup>reg</sup>/T<sup>eff</sup> ratio. RNAseq of tumour tissue demonstrated lower intrinsic immunogenicity in PRef samples, characterised by repressed IFN-γ and T<sup>eff</sup> signatures, with elevated myeloid infiltration. Conditional inference tree analysis identified IFN-γ signature downregulation combined with NLR ≥3 as the strongest contributor of PRef.</p></sec><sec id="S4"><title>Conclusions</title><p id="P6">PRef to A+B identifies a distinct biological entity characterised by unopposed systemic inflammation, myeloid cell infiltration and T-cell depletion. Targeting myeloid-mediated immunosuppression, particularly in patients with low IFN-γ signature expression and elevated NLR might enhance responsiveness to A+B.</p></sec></abstract></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P7">The prognostic outlook of patients with unresectable-advanced hepatocellular carcinoma (HCC) has remarkably improved in the last years due to the introduction of immune checkpoint inhibitors (ICI), which have shifted the expected median overall survival (OS) from approximately 10-13 months with sorafenib to up to 19.2 months with the combination of atezolizumab plus bevacizumab (A+B), the first immunotherapy combination to be introduced in clinical practice <sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R5">5</xref></sup>.</p><p id="P8">Whilst survival improvement from the use of Programmed Cell Death-1 (PD-1)/PD-1 ligand (PD-L1) inhibitor-containing combinations has been amply validated across several combination studies with Vascular Endothelial Growth Factor (VEGF), tyrosine kinase inhibitors (TKI) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors <sup><xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref></sup>, the proportion of patients that derive a measurable response remains confined to a minority ranging from 20 to 36% <sup><xref ref-type="bibr" rid="R6">6</xref></sup>.</p><p id="P9">Although achieving a response is not a universal pre-requisite to securing an overall survival benefit from all ICI combinations <sup><xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R4">4</xref></sup>, disease progression on anti-cancer immunotherapy remains invariably associated with a worse prognosis in HCC <sup><xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref></sup>. Therapeutic resistance to ICI remains an area of high unmet need, with patients experiencing either adaptive resistance following an initial response or primary resistance characterised by early disease progression on treatment. In solid tumours, primary refractoriness (PRef) to immunotherapy coincides with low intrinsic immunogenicity of the tumour, which can manifest itself through altered expression of tumour-associated antigens or lower neo-antigen load, defective epitope presentation and enrichment of immune co-inhibitory signals and immunosuppressive immune cells within the tumour microenvironment <sup><xref ref-type="bibr" rid="R10">10</xref></sup>. These characteristics are uniquely different from those driving adaptive resistance to ICI and bear a comparatively worse contribution to the prognosis of immunotherapy recipients <sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Acknowledging the fundamental differences in the immunobiology underlying the various patterns of resistance, the Society for Immunotherapy of Cancer (SITC) has developed consensus recommendations for defining resistance to ICI based on observed responses to treatment, providing a standardised framework to reproducibly identify PRef tumours in the clinic <sup><xref ref-type="bibr" rid="R11">11</xref></sup>.</p><p id="P10">Despite their demonstrated clinical utility in clinical research and routine practice, these criteria have not been validated in HCC, a disease where prognosis is not only dictated by tumour progression but uniquely influenced by concomitant liver dysfunction <sup><xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref></sup>. In addition, whilst efforts have been addressed to identify predictors of response to A+B, little attention has been dedicated to the phenotypic characterisation of those patients who will not derive upfront clinical benefit from A+B <sup><xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref></sup>.</p><p id="P11">In this study, we aimed to portray the clinical course of HCC patients who are primarily refractory to A+B. Using clinical data and pre-treatment HCC tissue samples from a large observational study and two landmark clinical trials in unresectable/advanced HCC, we sought to validate PRef to A+B as defined by SITC criteria and investigate the biological characteristics underlying PRef to identify prognostic factors and potential therapeutic targets to overcome primary resistance.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><sec id="S7"><title>Study design and clinical outcomes</title><p id="P12">Patient disposition across studied cohorts is summarized in <xref ref-type="fig" rid="F1">Figure 1</xref>. The study design and methods for AB-real <sup><xref ref-type="bibr" rid="R8">8</xref></sup>, GO30140 <sup><xref ref-type="bibr" rid="R16">16</xref></sup> and IMbrave150 have been described previously<sup><xref ref-type="bibr" rid="R1">1</xref></sup>.</p><p id="P13">The SITC consensus criteria were applied to identify primary resistance or refractoriness: PRef was defined as the achievement of progressive disease or stable disease lasting &lt;6 months as best overall response to ICI in all cohorts <sup><xref ref-type="bibr" rid="R11">11</xref></sup>. Responders were defined as patients who achieved a complete response (CR), a partial response (PR) or stable disease lasting ≥6 months as best overall response to ICI in all cohorts. Radiological response to treatment was assessed according to RECIST criteria v1.1. Treatment duration was calculated from the date of the first dose of A+B until discontinuation. OS was defined as the time from the first A+B dose of the treatment until death or last follow-up. Details on study design, patient assessments and response outcomes are described in <xref ref-type="supplementary-material" rid="SD2">Supplementary Methods</xref>.</p></sec><sec id="S8"><title>Machine-learning approach for tumour infiltrating lymphocytes (TILs) identification and quantification</title><p id="P14">We applied a supervised machine learning (ML) algorithm to 37 and 184 H&amp;E of Cohort 1 and Cohort 2-3, respectively, developed using QuPath (v.0.5.0) and followed the previously described procedure with some modifications <sup><xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref></sup> (<xref ref-type="fig" rid="F1">Figure 1</xref>). A detailed description of model development, training and quality verification can be found in the <xref ref-type="supplementary-material" rid="SD2">Supplementary Methods</xref>.</p></sec><sec id="S9"><title>Imaging Mass Cytometry (IMC)</title><p id="P15">Antibodies against human antigens were previously validated by immunohistochemistry (IHC), conjugated to IMC-compatible metal isotopes using the MaxPar X8 kit (Standard Biotools - 201300). Forty-three clinically annotated pre-treatment FFPE biopsy specimens were incubated with three rounds of Xylene, followed by decreasing concentrations of ethanol. Antigen retrieval was performed using Tris-EDTA (Ph9) at 98°C and tissues were blocked upon incubation with 3% Bovine Serum Albumin (ThermoFisher - A7906-100G) in PBS. Then, slides were incubated with the metal-conjugated antibody cocktail (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>) overnight at 4°C. The next day, the excess of antibody was washed with TBST 1X and PBS, and nuclei were stained using the Cell-ID™ Intercalator-Ir—125 µM (Standard Biotools - 201192A). Finally, tissues were left drying at room temperature, ready to be ablated using the Hyperion imaging device (Standard Biotools).</p><p id="P16">Once samples were imaged, a visual QC was performed to ensure good staining quality of the regions of interest (ROIs) used for the downstream analysis. A total of 441 ROIs were used for data generation. Data was exported in.TIFF format and cell segmentation was performed following the OPTIMAL pipeline <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. Single cells were clustered in cell types using the FlowSOM algorithm from FCS Express (Lic. no 75616), and then exported for neighbour joining analysis to generate the cell–cell interaction data. Cell-cell interaction analysis was performed as previously described<sup><xref ref-type="bibr" rid="R20">20</xref></sup>.</p></sec><sec id="S10"><title>Serum cytokines quantification</title><p id="P17">Peripheral blood samples were obtained immediately before the first administration of A+B in 182 patients of cohort 1 (<xref ref-type="fig" rid="F1">Figure 1</xref>). Following centrifugation at 1,000×g for 5 minutes; serum samples were stored at -80 °C. Serum cytokine concentrations were quantified using a cytometric bead array (560484, BD Biosciences) according to the manufacturer’s instructions.</p><p id="P18">In brief, the capture beads were incubated with serum samples and the detection reagent for 3 hours at room temperature. After several washes, cytokine-bead complexes were measured using a flow cytometer (Beckman Coulter), and the data were analysed using the FlowJo software (Tree Star Inc.).</p></sec><sec id="S11"><title>Tissue gene expression analysis</title><p id="P19">Differential gene expression analysis was performed with DESeq2, comparing responders and PRef. Significant differential expression was defined as an absolute log<sub>2</sub> fold-change of &gt;1 and an adjusted <italic>P</italic> &lt; 0.05.</p><p id="P20">xCell deconvolution analysis was applied to baseline RNA-seq data, and cell type enrichment scores were compared between PRef and responders using Student’s t-test with Benjamini–Hochberg correction.</p><p id="P21">We calculated gene signature scores for each sample as the arithmetic mean of log2(CPM) expression of all genes in a given signature (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). Gene set enrichment analysis (GSEA) was performed using the MultiGSEA package v.1.1.99 with default parameters, and the Hallmark gene set collection from the molecular signatures database collection (MSigDB) and the CAMERA method for multiple hypothesis testing <sup><xref ref-type="bibr" rid="R21">21</xref></sup>.</p></sec><sec id="S12"><title>Statistical analysis</title><p id="P22">Statistical analyses were performed using R v.4.3.1. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test. Hazard ratios (HR) with 95% CIs and p values were determined using a stratified Cox proportional hazards model and log-likelihood test. The proportional hazards assumption was validated using Schoenfeld residuals.</p><p id="P23">Multivariate adjustment included key clinical and laboratory variables, detailed in the <xref ref-type="supplementary-material" rid="SD2">Supplementary Methods</xref>. To assess the association between SITC-defined response and survival outcomes while minimizing immortal time bias, we employed a time-dependent Cox proportional hazards model. Response status was treated as a time-varying variable, with patients initially classified as PRef. Those who remained progression-free beyond six months were reclassified as responders, while others remained PRef. This approach improved the accuracy of hazard estimates and prevented artificial survival advantages.</p><p id="P24">To explore determinants of PRef, we applied a conditional inference tree (CTree) analysis using the party R package, visualising results with Sankey diagrams. The biomarker-evaluable population was analysed separately in Cohorts 2 and 3 to mitigate batch effects in RNA-seq data but was combined for CTree analysis, where RNA signatures were reduced to categorical variables. Detailed methods in the <xref ref-type="supplementary-material" rid="SD2">Supplementary Methods</xref>.</p></sec></sec><sec id="S13" sec-type="results"><title>Results</title><sec id="S14"><title>Patient Cohorts</title><p id="P25">Of the 3 parallel patient cohorts derived from prospective observational and randomized clinical studies (<xref ref-type="fig" rid="F1">Figure 1A</xref>), Cohort 1 consisted of 1296 patients included in the prospectively maintained database AB-real, a subgroup of whom had pre-treatment tissue available for IMC (n=43) and serum available for cytokine/chemokine quantification (n=182). Cohorts 2 and 3 included 645 patients treated in the GO 30140 (n=222) phase I and IMbrave 150 (n=423) phase III clinical trials, respectively, with bulk transcriptome data and TIL quantification (n=229 and n=184 respectively) (<xref ref-type="fig" rid="F1">Figure 1B</xref>). After removing patients who did not meet inclusion criteria, 677 and 378 patients were evaluated for SITC criteria for cohorts 1 and 2-3, respectively (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>).</p></sec><sec id="S15"><title>Primary refractoriness to A+B is associated with poor oncological outcomes in unresectable HCC</title><p id="P26">We first assessed the relationship between PRef and OS and used Cohort 1 as a training set and Cohort 2-3 as validation.</p><p id="P27">Among the 677 patients in Cohort 1, 313 (46%) were classified as PRef in Cohort 1 due to PD as first response (220, 70.3%) or SD &lt;6 months (93, 29.3%). In Cohorts 2-3, 168 (44%) patients were identified as PRef due to PD (91, 54.2%) or SD&lt;6 months (77, 45.8%).</p><p id="P28">Across Cohorts, PRef patients had a higher percentage of Barcelona Clinic Liver Cancer (BCLC) stage C disease (Cohort 1: 80% vs. 72%, <italic>p</italic>=0.0017; Cohort 2-3: 92% vs. 79%, <italic>p=</italic>0.001), and higher NLR ≥3 (Cohort 1: 60% vs. 37%, <italic>p</italic>&lt;0.001; Cohort 2-3: 58% vs. 34%, <italic>p</italic>&lt;0.001) compared to responders. Clinical characteristics and outcomes are summarised in <xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 3-4</xref> and <xref ref-type="supplementary-material" rid="SD2">Supplementary Results</xref>.</p><p id="P29">After a median follow-up of 20.9 (95% CI 19.8–22.0) (Cohort 1) and 14.3 (95% CI 8.1–21.1) months (Cohort 2-3), 308 (45.9%) patients and 207 patients (54.8%) were alive at the data cut-off in Cohort 1 and Cohort 2-3, respectively. Median OS was significantly worse in PRef vs. responders (Cohort 1: 7.3 vs. 31.5 months, HR 3.7, 95%CI 2.8–8.5, p&lt;0.0001; Cohort 2- 3: 10.8 vs. NR, HR 4.6, 95%CI 3.3–6.3, p&lt;0.0001, <xref ref-type="fig" rid="F1">Figure 1C-D</xref>). To address the risk of immortal time bias, we performed time-dependent multivariate models, which confirmed PRef status to be associated with the highest risk of mortality across Cohorts (Cohort 1: HR 4.0, 95% CI 2.8–5.5 p&lt;0.001; Cohorts 2-3: HR 4.9, 95% CI 3.6–6.7, p&lt;0.001) alongside NLR ≥3, α-fetoprotein (AFP) and Albumin-Bilirubin (ALBI) grade (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 5</xref>).</p><p id="P30">To further investigate the clinical characteristics of PRef, the NLR was chosen as a marker of systemic inflammation<sup><xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref></sup>. PRef patients exhibited a higher baseline inflammatory status compared to responders as measured by median NLR of 3.6 vs. 2.7 in Cohort 1 and 3.3 vs 2.4 in Cohort 2-3 (p&lt;0.001). The proportion of patients with NLR ≥3 was also higher across PRef vs responders in Cohort 1 (63% vs 40%, p&lt;0.001) and Cohorts 2-3 (65% vs. 35%, p&lt;0.001, <xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 3-4</xref>).</p></sec><sec id="S16"><title>PRef is independent of pre-treatment TIL density</title><p id="P31">We sought to determine whether PRef patients harboured a differentially immunogenic tumour microenvironment compared to responders and first investigated differences in tumour-infiltrating lymphocytes (TILs) density across groups, electing TILs as <italic>bona fide</italic> markers of spontaneously immunogenic tumours <sup><xref ref-type="bibr" rid="R24">24</xref></sup>. We applied a pre-optimised ML algorithm to evaluate the differential density of TILs in a total of 37 patients treated with A+B in Cohort 1 and 184 patients accrued in Cohort 2-3 who had digitally available H&amp;E slides. Median cell density was 141 (IQR 419) and 417 (IQR 494) cell/mm<sup>2</sup> of assayed tissue in Cohort 1 and Cohort 2-3 respectively and not different in PRef compared to responders (Cohort 1: 138 vs 169 cell/mm2, p=0.74: Cohort 2-3 442 vs 399 cell/mm<sup>2</sup>, p=0.57, <xref ref-type="fig" rid="F2">Figure 2A-B</xref>).</p></sec><sec id="S17"><title>Primary refractoriness to A+B is associated with a unique immune composition of the HCC TME</title><p id="P32">We next performed in-depth spatial immune phenotyping of the tumour microenvironment to characterise the mechanisms underpinning PRef to A+B. We performed highly multiplexed IMC in a subset of Cohort 1 patients with pre-treatment FFPE tissue available for analysis (n=43) (<xref ref-type="fig" rid="F2">Figure 2C</xref>). In total, we acquired 441 high-dimensional histopathology images representing 43 patients with HCC; 19 PRef and 24 responders (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Images were segmented into 291,642 total cells, clustered and then annotated using the OPTIMAL IMC analysis pipeline <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. Using this approach we classified multiple tumour cell populations, various stromal and vascular cell types as well as 11 individual immune cell populations representing a range of lymphocyte and myeloid populations (<xref ref-type="fig" rid="F2">Figure 2E</xref>). Quantification of these major cellular compartments showed no difference in the number of tumour, stromal, endothelial or immune cells in PRef compared to responders (<xref ref-type="fig" rid="F2">Figure 2F-H</xref>). Therefore, a deeper and more detailed analysis of cell compartments was performed.</p><p id="P33">When we compared the abundance of individual cell types, we found that CD163<sup>+</sup> tumour-associated macrophages (CD163<sup>+</sup> TAMs), encompassing the entire spectrum of CD163 high (CD163<sup>Hi</sup>) and CD163 intermediate (CD163<sup>Int</sup>) expression, were enriched in PRef patients, being the CD163<sup>Int</sup> TAMs the individual cell subpopulation more strongly associated with PRef (p&lt;0.0001). These were followed by vascular cancer-associated fibroblasts (vCAFs) (p&lt;0.05). Moreover, although not statistically significant, anti-tumour entities like CD8<sup>+</sup> T-cells, CD4<sup>+</sup> T helpers, dendritic cells and CD16<sup>hi</sup> CD56<sup>dim</sup> NK cells were enriched in responders, whereas pro-tumour cell types such as neutrophils, CD4<sup>+</sup>FoxP3<sup>+</sup> T regulatory cells (FoxP3<sup>+</sup> T<sup>reg</sup>) and a diversity of other CAF subtypes were enriched in PRef (<xref ref-type="fig" rid="F3">Figure 3A-B</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2B</xref>).</p><p id="P34">In addition, the ratio between FoxP3<sup>+</sup> T<sup>reg</sup> and Granzyme B<sup>+</sup> CD8<sup>+</sup> T-cells (GzmB<sup>+</sup> CD8<sup>+</sup> T-cells), termed as T<sup>reg</sup> / T<sup>eff</sup> ratio, was significantly higher in PRef vs. responders (p&lt;0.01, <xref ref-type="fig" rid="F3">Figure 3C-D</xref>). Cell-cell interaction analysis revealed that PRef patients’ tumours in general are enriched for interactions between anti-tumour immune cells (CD8<sup>+</sup> T cells, CD4<sup>+</sup> T helpers, CD16<sup>Hi</sup> CD56<sup>Dim</sup> NK cells) and immunosuppressive cells (Neutrophils, CD163<sup>Int</sup> and CD163<sup>Hi</sup> TAMs and FoxP3<sup>+</sup> Tregs). Specifically, PRef tumours were enriched for interactions between Tregs and GzmB<sup>+</sup>CD8<sup>+</sup> T cells, neutrophils with CD4<sup>+</sup> T helpers and CD4<sup>+</sup> T helpers with CD163<sup>Int</sup> and CD163<sup>Hi</sup> TAMs (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3A</xref>).</p><p id="P35">Because primary refractoriness was associated with higher levels of systemic inflammation, we contrasted the characteristics of neutrophil and lymphocyte infiltration within the tumour in patients with NLR ≥3 and &lt;3. Patients with peripheral blood NLR ≥3 harboured tumours with higher neutrophil/lymphocyte infiltration within the HCC TME (p = 0.0069) (<xref ref-type="fig" rid="F3">Figure 3E-G</xref>). Cell-cell interaction analysis showed that the tumours of patients with a high NLR were specifically enriched for interactions between anti-tumour immune cells and neutrophils, and not immunosuppressive cells in general like those identified comparing PRef and responders (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3B</xref>).</p><p id="P36">To further characterise the relationship between PRef and systemic inflammation, we measured a panel of baseline serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, IFNγ, and TNFα) in a subset of Cohort 1 patients (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 4</xref>). Among these, IL-6 -a pro-inflammatory cytokine and a well-established marker of resistance to immunotherapy in both tissue and blood <sup><xref ref-type="bibr" rid="R25">25</xref></sup> had a higher concentration in PRef versus responders expressed between PRef and responders (p=0.0029) (<xref ref-type="fig" rid="F3">Figure 3H</xref>). Additionally, patients with higher IL-6 levels had reduced OS and PFS compared to those with lower IL-6 levels (<xref ref-type="fig" rid="F3">Figure 3I</xref>).</p></sec><sec id="S18"><title>Immunosuppressive myeloid cell infiltration is a robust hallmark of primary refractoriness to A+B and impairs prognosis</title><p id="P37">To validate the myeloid cell / T cell imbalance seen in PRef identified in Cohort 1, we used bulk RNAseq data from pre-treatment tumour samples from Cohorts 2 and 3. Demographic and baseline characteristics in the biomarker-evaluable patients were generally consistent with those in the whole population recruited to the GO30140 and IMBrave150 trials (<xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 6</xref>) and so were clinical outcomes (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5-6</xref>).</p><p id="P38">We first performed an enrichment cell analysis and evaluated several gene signatures reflective of adaptive and innate immunity in Cohort 2 pre-treatment samples. Cell enrichment analysis on RNASeq datasets confirmed IMC data in portraying PRef as associated with an immunosuppressive, myeloid-enriched landscape characterised by CD4<sup>+</sup> and CD8<sup>+</sup> T-cell depletion (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 7</xref>).</p><p id="P39">In an attempt to identify distinctive molecular drivers of PRef, we performed genome-wide differential expression (DEG) analysis in Cohort 2 patients (n=119) as a discovery Cohort and then independently verified in Cohort 3 patients (n=110). We identified differentially expressed genes specifically dysregulated in PRef compared to responders associated with immunosuppression and senescence. These included repression of T-cell effector genes including <italic>IFNG, GZMB, CD8A</italic> and <italic>FASLG</italic> transcriptional traits predictive of immunotherapy response<sup><xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R29">29</xref></sup>. PRef samples were also characterised by a complex gene expression profile with upregulation of immunosuppressive transcripts involved in myeloid infiltration (i.e. S100A9, CXCL5, NOS2), systemic inflammation and T<sup>reg</sup> infiltration (i.e. <italic>IL-6, AREG</italic>), evasion from phagocytosis (i.e. <italic>CD24</italic>), stromal activity (i.e. ACTA1), hypoxia and acidosis (i.e. CA12, ATP6V1B1), and microenvironment alteration (i.e. <italic>APOA4</italic>). While responders possessed an enrichment in T and NK cell identity plus activation transcripts (i.e. CD8A, NCR1, NCAM1, NKG7, GZMB, FASLG, TXK, IFNG), antigen presentation (i.e. HLA.DQA1), platelets (ITGA2B), and anti-tumour myeloid activity (CXCL9). These findings were supported by hallmark GSEA, which confirmed PRef samples to harbour a significant enrichment of immunosuppressive pathways including TNF-α, TGF-β, Notch, and signatures related to epithelial-mesenchymal transition, angiogenesis and hypoxia. These features were mirrored by a significant up-regulation in gene expression profiles relating to adaptive immunity such as interferon alpha (IFN-α) and gamma (IFN-γ) in responding patients, to suggest an imbalance in intrinsic tumour immunogenicity across patient groups (<xref ref-type="fig" rid="F4">Figure 4A-B</xref>).</p><p id="P40">Paired analyses performed in Cohort 3 patients demonstrated that PRef samples were associated with up-regulation of similar immunosuppressive pathways including Notch and hypoxia signalling pathways (<xref ref-type="fig" rid="F4">Figure 4B</xref>), validating findings from Cohort 2 RNAseq experiments. Similarly to Cohort 2, several gene sets previously reported to be associated with response to immunotherapy reflective of an inflamed/immune enriched and IFN-γ rich microenvironment were downregulated in PRef and especially expressed in responding patients, supporting the immunosuppressive phenotype typical of PRef (<xref ref-type="fig" rid="F4">Figure 4B</xref>).</p><p id="P41">We then analysed immune signatures and observed a significant reduction in key immune effector populations, including IFN-γ (p&lt;0.001), T<sup>eff</sup> (p=0.001), NK (p=0.04) and T<sup>cyt</sup> (p=0.007) signatures (<xref ref-type="fig" rid="F4">Figure 4C</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 8</xref>). While no significant differences were observed in M1/M2 tumour-associated macrophages (TAM) signatures (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 8</xref>), we assessed the CXCL9:SPP1 ratio, a recently identified marker of macrophage polarity. We observed a differential expression in our Cohort, with PRef characterised by a low CXCL9:SPP1 ratio (p=0.018) (<xref ref-type="fig" rid="F4">Figure 4D</xref>), consistent with hypoxia-driven immune suppression and tumour progression. We also observed a significantly higher myeloid:T<sup>eff</sup> cells ratio (p=0.0003) and MDSC/T<sub>eff</sub> ratio (p=0.0009) (<xref ref-type="fig" rid="F4">Figure 4E-F</xref>), confirming the IMC data.</p></sec><sec id="S19"><title>The immune contexture typical of PRef is independently associated with poor patients’ survival</title><p id="P42">As a further step, we evaluated whether the immune signatures defining PRef were independently associated with patient’s survival. Patients with low expression of the IFN-γ, and T<sup>eff</sup> signatures, along with high MDSC:T<sup>eff</sup> and myeloid:T<sup>eff</sup> cell ratios, had significantly worse OS (IFN-γ signature: HR 2.82, 95%CI 1.42–5.6, p=0.002; T<sup>eff</sup> signature: HR 2.27, 95%CI 1.16-4.46, p=0.014: MDSC:T<sup>eff</sup> cells ratio signature: HR 2.54, 95%CI 1.28–5.04, p=0.006; myeloid:T<sup>eff</sup> cells ratio signature: HR 3.11, 95% CI 1.56–6.2, p&lt;0.001, <xref ref-type="fig" rid="F4">Figure 4C, E-F</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 8C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 9</xref>).</p></sec><sec id="S20"><title>Model-based recursive partitioning identifies systemic inflammation and depleted tumour immunogenicity as determinants of primary refractoriness to A+B</title><p id="P43">To verify the relative contribution of routine pre-treatment variables over the underlying tumour immune contexture as a determinant of PRef to A+B, we integrated clinical and transcriptome data from Cohorts 2 and 3 using a CTree.</p><p id="P44">We selected NLR and ALBI given their independent prognostic role and combined these with IFN-γ, and T<sup>eff</sup> signatures, along with the MDSC:T<sup>eff</sup> and myeloid:T<sup>eff</sup> cell ratio signatures, based on the prognostic relevance demonstrated before. AFP levels were excluded due to the high proportion (&gt;50%) of missing values in the biomarker-evaluable patients.</p><p id="P45">This analysis provided a hierarchical disposition of characteristics independently associated with PRef. Notably, repression of IFN-γ related transcripts emerged as the most significant factor associated with PRef, especially when combined with high systemic inflammation, as indicated by an NLR≥3, contributing to shape 73.8% of the risk of PRef in these patients. Conversely, IFN-γ signature overexpression did not entirely preclude PRef, especially in patients with an elevated myeloid:T<sup>eff</sup> ratio, which doubled the risk compared to those with lower ratios (45% vs. 19.4%, <xref ref-type="fig" rid="F4">Figure 4G</xref>). Consistent with these findings, Kaplan–Meier survival analysis demonstrated significantly different overall survival outcomes across the identified patient subgroups (<xref ref-type="fig" rid="F4">Figure 4H</xref>).</p></sec></sec><sec id="S21" sec-type="discussion"><title>Discussion</title><p id="P46">In a rapidly expanding treatment landscape, where multiple ICI combinations and TKIs are available for the treatment of unresectable-advanced HCC, early identification and improved mechanistic understanding of primary resistance to treatment represents a clinical imperative to broaden the benefit of anti-cancer immunotherapy in HCC.</p><p id="P47">Leveraging large, globally accrued patient datasets, including landmark clinical trials of A+B in this indication, our study provides solid and validated criteria to define primary therapeutic resistance to A+B. We found that PRef, defined as the achievement of early disease progression or short-lived HCC stabilisation, affects approximately 45% of patients treated with A+B in clinical trials and routine practice.</p><p id="P48">This substantial subset of patients exhibits distinctive clinical and immunological features. PRef was more likely in patients with advanced-stage HCC and was associated with worse ALBI grade and elevated NLR. Hypoalbuminemia and high NLR, two recognised biomarkers of systemic inflammation <sup><xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref></sup>, were strongly associated with PRef, suggesting an unopposed pro-inflammatory state in these patients. Consistent with these findings, PRef patients exhibited higher intra-tumoural expression and elevated circulating IL-6 levels, a circulating cytokine that controls the switch from acute to chronic inflammation, reinforcing the link between systemic inflammation and an immune microenvironment polarised towards an immune suppressive status <sup><xref ref-type="bibr" rid="R25">25</xref></sup>.</p><p id="P49">Given the strong association between PRef and systemic inflammation, we next examined the TME to dissect the underlying immune landscape associated with treatment failure. Using IMC on pre-treatment biopsies, we found that PRef tumours were characterised by significantly denser myeloid infiltration, T-cell depletion and a more strongly immunosuppressive TME. The presence of a myeloid-dominant phenotype was further and independently validated in clinical trial cohorts, demonstrating that PRef represents a distinct IFN-γ-low, myeloid-enriched immune state.</p><p id="P50">Among myeloid subsets, TAMs emerged as a key determinant of PRef. Our IMC analysis revealed that PRef tumours exhibited an increased density of CD163<sup>+</sup> TAMs, including the different spectrums of CD163 expression level, CD163<sup>Hi</sup> and CD163<sup>Int</sup> M2-like TAMs, showing the last ones the strongest association with PRef patients. CD163<sup>Int</sup> TAMs are macrophages that possess both newly recruited and immunomodulatory phenotypes, previously reported to cause chronic liver disease<sup><xref ref-type="bibr" rid="R32">32</xref></sup>, probably by suppressing T-cell lymphocytes via immune checkpoint axes or secretion of factors like Osteopontin.</p><p id="P51">To refine our understanding of TAM polarisation, we evaluated CXCL9 and SPP1 (the gene encoding Osteopontin) expression as markers of anti- and pro-tumour macrophage polarisation in our pre-treatment samples. CXCL9 polarisation, induced by IFN-γ, is associated with an anti-tumour immune response, while SPP1 polarisation is upregulated under hypoxic conditions and linked to immune suppression<sup><xref ref-type="bibr" rid="R33">33</xref></sup>. In our study, whereas not statistically significant, the CXCL9:SPP1 ratio seems to be associated with survival outcomes from A+B, with a low ratio consistently observed in PRef patients. Furthermore, these patients exhibited low IFN-γ signature expression and enrichment of hypoxia-related pathways, reinforcing the link between an immunosuppressive TME and primary resistance.</p><p id="P52">Beyond individual markers, our findings revealed a broader imbalance in the myeloid compartment of PRef tumours. While NLR has long been recognized as a prognostic indicator in oncology <sup><xref ref-type="bibr" rid="R22">22</xref></sup>, our work first described a direct parallel between elevated peripheral NLR and the enrichment of immunosuppressive myeloid cells within the TME. The strong correlation between elevated NLR and intratumoral immune composition suggests a systemic-local immune axis that may contribute to immunotherapy resistance. This finding has the potential for stratifying HCC patients that can benefit from neutrophil-based therapies, currently in clinical trials<sup><xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup>.</p><p id="P53">Whilst independently associated with prognosis and refractoriness to treatment, the systemic pro-inflammatory response associated with PRef is known to be conditioned by redundant and pleiotropic molecular drivers. For this reason, we opted to integrate findings from our transcriptomic experiments and review of patient data to define the hierarchical relationships among resistance mechanisms. Using CTree we identified IFN-γ repression as the primary determinant of PRef risk, particularly in the presence of elevated systemic inflammation (NLR ≥3). Presence of these two, independent traits defined a high-risk subgroup with a 74% probability of PRef, representing the most unfavourable biological scenario. Notably, even among patients with high IFN-γ expression, an elevated myeloid:T<sup>eff</sup> cell ratio more than doubled the risk of PRef (45% vs. 19.4%), underscoring the critical role of the balance between effector and suppressive immune populations in shaping treatment outcomes. This hierarchical model not only provides deeper insights into resistance mechanisms but also supports patient stratification based on the dominant resistance pathway, with potential implications for personalized therapeutic strategies.</p><p id="P54">Several limitations of our study should be acknowledged. Although our multi-cohort approach provides robust validation of determinants and clinical characteristics of patients with PRef to A+B, the retrospective design of our study exposes the risk selection bias, particularly in the observational cohort. In addition, analyses of tissue samples were performed on archival samples, which may not fully reflect the dynamic changes in the TME at the time of treatment initiation. Whilst convergent, IMC and transcriptomic analyses were conducted on different patient subsets with non-overlapping experimental readouts, potentially limiting direct cross-comparisons between these datasets. While we identified key biological features associated with PRef, the causal relationships among these factors remain to be fully elucidated. Lastly, while our conditional inference tree model offers a framework for patient stratification, prospective validation in independent cohorts is necessary before clinical implementation.</p><p id="P55">Despite these limitations, our findings have significant implications for drug development and study design in HCC. The prominence of myeloid-mediated immunosuppression suggests that targeting this axis could enhance the efficacy of A+B. Several emerging therapeutic strategies aim to counteract myeloid-driven resistance by modulating macrophage and myeloid cell function within the tumour microenvironment. Among these, combining A+B with anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitors (i.e. tiragolumab) has shown promise, leveraging both T-cell activation and myeloid modulation to enhance anti-tumour immunity<sup><xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref></sup>. In patients with NSCLC, high intratumoral T<sup>reg</sup> and myeloid infiltration correlated with improved benefit from atezolizumab plus tiragolumab versus atezolizumab alone<sup><xref ref-type="bibr" rid="R39">39</xref></sup>, suggesting preferential activity in tumours that share immunobiologic characteristics with PRef HCC. Other strategies to overcome myeloid-driven tumour immune escape may involve blocking CD24, another hallmark of PRef that suppresses macrophage phagocytosis via Siglec-10<sup><xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R41">41</xref></sup>, LILRB2 (ILT4), known to transmit inhibitory signals in macrophages<sup><xref ref-type="bibr" rid="R42">42</xref></sup> (NCT04524871), or use of CSF1R inhibitors, which deplete or reprogramme immunosuppressive TAMs <sup><xref ref-type="bibr" rid="R43">43</xref></sup>, as well as therapies targeting the SIRPα-CD47 axis, which enhance phagocytosis <sup><xref ref-type="bibr" rid="R44">44</xref></sup>. Our hierarchical model suggests that patients with repressed IFN-γ signalling and NLR ≥3, who have a 74% probability of PRef, may represent prime candidates for myeloid-targeting combination strategies.</p><p id="P56">In conclusion, our study provides the first comprehensive characterisation of PRef to A+B in HCC, establishing PRef as a distinct biological entity defined by systemic inflammation, myeloid cell infiltration, and T-cell depletion. These findings not only enhance our understanding of immunotherapy resistance in HCC but also lay the groundwork for biomarker-driven combination strategies aimed at overcoming primary resistance. Future studies should focus on the prospective validation of these findings, elucidation of resistance evolution during treatment, and evaluation of targeted interventions to enhance immunotherapy efficacy in resistant patient populations.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Figures and Tables</label><media xlink:href="EMS207151-supplement-Supplementary_Figures_and_Tables.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d2aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Methods and Results</label><media xlink:href="EMS207151-supplement-Supplementary_Methods_and_Results.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d2aAcEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Acknowledge</title><p>The authors would like to acknowledge the following sources of funding: European Society of Medical Oncology (ESMO) Translational Fellowship (to PL).</p><sec id="S23"><title>Funding</title><p>This research was funded by the National Research Foundation of Korea (NRF) grants, supported by the Korean government (MSIT): grant numbers NRF 2023R1A2C2004339 to H.J.C.</p><p>J.L. is supported by an Academy of Medical Sciences Springboard award (SBF009\1103), Royal Society Research Grant (RG\R2\232323), JGW Patterson Foundation primer grant, CRUK program grants (DRCRPG-Nov22/100007) and an MRC project grant (MR/Y003365/1). E.R.G funded by W.E. Harker PhD studentship (C0260N3038). J.L. and E.R.G are supported by a NIHR BRC project grant (NIHR203309).</p></sec></ack><sec id="S24" sec-type="data-availability"><title>Data availability</title><p id="P57">All clinical, raw RNA-seq data for the GO30140 and IMbrave150 trials are deposited in the European Genome-Phenome Archive under accession no. <ext-link ext-link-type="uri" xlink:href="https://ega-archive.org/studies/EGAS00001005503">EGAS00001005503</ext-link>. Qualified researchers may request access to individual patient-level data through the clinical study data request platform (<ext-link ext-link-type="uri" xlink:href="https://vivli.org/">https://vivli.org/</ext-link>). Further details on Roche’s criteria for eligible studies are available at <ext-link ext-link-type="uri" xlink:href="https://vivli.org/members/ourmembers">https://vivli.org/members/ourmembers</ext-link>. For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see <ext-link ext-link-type="uri" xlink:href="https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm">https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm</ext-link>.</p></sec><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>20</issue><fpage>1894</fpage><lpage>1905</lpage><pub-id pub-id-type="pmid">32402160</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma</article-title><source>Ann Oncol</source><year>2024</year><volume>35</volume><issue>5</issue><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">38382875</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2022</year><volume>76</volume><issue>4</issue><fpage>862</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">34902530</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimassa</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><etal/></person-group><article-title>Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC</article-title><source>J Hepatol</source><year>2025</year><pub-id pub-id-type="pmid">40222621</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Dawson</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2025</year><volume>36</volume><issue>5</issue><fpage>491</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">39986353</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulgenzi</surname><given-names>CAM</given-names></name><name><surname>Scheiner</surname><given-names>B</given-names></name><name><surname>Korolewicz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials</article-title><source>JHEP Rep</source><year>2023</year><volume>5</volume><issue>5</issue><elocation-id>100702</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100702</pub-id><pub-id pub-id-type="pmcid">PMC10070142</pub-id><pub-id pub-id-type="pmid">37025943</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Castet</surname><given-names>F</given-names></name><name><surname>Heikenwalder</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunotherapies for hepatocellular carcinoma</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><issue>3</issue><fpage>151</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">34764464</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulgenzi</surname><given-names>CAM</given-names></name><name><surname>Cheon</surname><given-names>J</given-names></name><name><surname>D’Alessio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study</article-title><source>Eur J Cancer</source><year>2022</year><volume>175</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">36148739</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campani</surname><given-names>C</given-names></name><name><surname>Vallot</surname><given-names>A</given-names></name><name><surname>Ghannouchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab</article-title><source>Hepatology</source><year>2024</year><volume>79</volume><issue>1</issue><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">37870270</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</article-title><source>Cell</source><year>2017</year><volume>168</volume><issue>4</issue><fpage>707</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id><pub-id pub-id-type="pmcid">PMC5391692</pub-id><pub-id pub-id-type="pmid">28187290</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluger</surname><given-names>H</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>3</issue><pub-id pub-id-type="doi">10.1136/jitc-2022-005921</pub-id><pub-id pub-id-type="pmcid">PMC10016305</pub-id><pub-id pub-id-type="pmid">36918224</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabibbo</surname><given-names>G</given-names></name><name><surname>Celsa</surname><given-names>C</given-names></name><name><surname>Battaglia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death</article-title><source>Clin Cancer Res</source><year>2025</year><volume>31</volume><issue>3</issue><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">39576248</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celsa</surname><given-names>C</given-names></name><name><surname>Cabibbo</surname><given-names>G</given-names></name><name><surname>Fulgenzi</surname><given-names>CAM</given-names></name><etal/></person-group><article-title>Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment</article-title><source>Hepatology</source><year>2025</year><volume>81</volume><issue>3</issue><fpage>837</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">39028886</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuyns</surname><given-names>S</given-names></name><name><surname>Pique-Gili</surname><given-names>M</given-names></name><name><surname>Esteban-Fabro</surname><given-names>R</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jhep.2024.12.016</pub-id><pub-id pub-id-type="pmcid">PMC12086051</pub-id><pub-id pub-id-type="pmid">39709141</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Abbas</surname><given-names>AR</given-names></name><name><surname>de Galarreta</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>8</issue><fpage>1599</fpage><lpage>1611</lpage><pub-id pub-id-type="pmid">35739268</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>6</issue><fpage>808</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">32502443</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakaee</surname><given-names>M</given-names></name><name><surname>Adib</surname><given-names>E</given-names></name><name><surname>Ricciuti</surname><given-names>B</given-names></name><etal/></person-group><article-title>Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC</article-title><source>JAMA Oncol</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.4933</pub-id><pub-id pub-id-type="pmcid">PMC9673028</pub-id><pub-id pub-id-type="pmid">36394839</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><name><surname>Loughrey</surname><given-names>MB</given-names></name><name><surname>Fernandez</surname><given-names>JA</given-names></name><etal/></person-group><article-title>QuPath: Open source software for digital pathology image analysis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><elocation-id>16878</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-17204-5</pub-id><pub-id pub-id-type="pmcid">PMC5715110</pub-id><pub-id pub-id-type="pmid">29203879</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>B</given-names></name><name><surname>Nicorescu</surname><given-names>I</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><etal/></person-group><article-title>OPTIMAL: An OPTimized Imaging Mass cytometry AnaLysis framework for benchmarking segmentation and data exploration</article-title><source>Cytometry Part A</source><year>2024</year><volume>105</volume><issue>1</issue><fpage>36</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.24803</pub-id><pub-id pub-id-type="pmcid">PMC10952805</pub-id><pub-id pub-id-type="pmid">37750225</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>E</given-names></name><name><surname>Yu</surname><given-names>MW</given-names></name><name><surname>Maritan</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Single-cell spatial immune landscapes of primary and metastatic brain tumours</article-title><source>Nature</source><year>2023</year><volume>614</volume><issue>7948</issue><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05680-3</pub-id><pub-id pub-id-type="pmcid">PMC9931580</pub-id><pub-id pub-id-type="pmid">36725935</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canzler</surname><given-names>S</given-names></name><name><surname>Hackermuller</surname><given-names>J</given-names></name></person-group><article-title>multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data</article-title><source>BMC Bioinformatics</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>561</fpage><pub-id pub-id-type="doi">10.1186/s12859-020-03910-x</pub-id><pub-id pub-id-type="pmcid">PMC7720482</pub-id><pub-id pub-id-type="pmid">33287694</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guthrie</surname><given-names>GJ</given-names></name><name><surname>Charles</surname><given-names>KA</given-names></name><name><surname>Roxburgh</surname><given-names>CS</given-names></name><etal/></person-group><article-title>The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2013</year><volume>88</volume><issue>1</issue><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">23602134</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfredi</surname><given-names>GF</given-names></name><name><surname>Fulgenzi</surname><given-names>CAM</given-names></name><name><surname>D’Alessio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma</article-title><source>Digestive and Liver Disease</source><year>2024</year><volume>56</volume><fpage>S8</fpage><lpage>S9</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presti</surname><given-names>D</given-names></name><name><surname>Dall’Olio</surname><given-names>FG</given-names></name><name><surname>Besse</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review</article-title><source>Crit Rev Oncol Hematol</source><year>2022</year><volume>177</volume><elocation-id>103773</elocation-id><pub-id pub-id-type="pmid">35917885</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>DT</given-names></name><name><surname>Appenheimer</surname><given-names>MM</given-names></name><name><surname>Evans</surname><given-names>SS</given-names></name></person-group><article-title>The two faces of IL-6 in the tumor microenvironment</article-title><source>Semin Immunol</source><year>2014</year><volume>26</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2014.01.008</pub-id><pub-id pub-id-type="pmcid">PMC3970580</pub-id><pub-id pub-id-type="pmid">24602448</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgovanovic</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Roles of IFN-gamma in tumor progression and regression: a review</article-title><source>Biomark Res</source><year>2020</year><volume>8</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s40364-020-00228-x</pub-id><pub-id pub-id-type="pmcid">PMC7526126</pub-id><pub-id pub-id-type="pmid">33005420</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurkmans</surname><given-names>DP</given-names></name><name><surname>Basak</surname><given-names>EA</given-names></name><name><surname>Schepers</surname><given-names>N</given-names></name><etal/></person-group><article-title>Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer</article-title><source>J Immunother Cancer</source><year>2020</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1136/jitc-2020-000586</pub-id><pub-id pub-id-type="pmcid">PMC7254154</pub-id><pub-id pub-id-type="pmid">32461348</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fumet</surname><given-names>JD</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Ledys</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy</article-title><source>Br J Cancer</source><year>2018</year><volume>119</volume><issue>8</issue><fpage>950</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0220-9</pub-id><pub-id pub-id-type="pmcid">PMC6203820</pub-id><pub-id pub-id-type="pmid">30318514</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Ibrahim</surname><given-names>ML</given-names></name><name><surname>Redd</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy</article-title><source>Mol Cancer Res</source><year>2019</year><volume>17</volume><issue>2</issue><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-18-0455</pub-id><pub-id pub-id-type="pmcid">PMC6359951</pub-id><pub-id pub-id-type="pmid">30429213</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halazun</surname><given-names>KJ</given-names></name><name><surname>Hardy</surname><given-names>MA</given-names></name><name><surname>Rana</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><issue>1</issue><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">19561458</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrest</surname><given-names>LM</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>McArdle</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><issue>6</issue><fpage>1028</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601242</pub-id><pub-id pub-id-type="pmcid">PMC2376960</pub-id><pub-id pub-id-type="pmid">12966420</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillot</surname><given-names>A</given-names></name><name><surname>Winkler</surname><given-names>M</given-names></name><name><surname>Silva Afonso</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression</article-title><source>Hepatology (Baltimore, Md)</source><year>2023</year><volume>78</volume><issue>1</issue><pub-id pub-id-type="pmid">36630995</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bill</surname><given-names>R</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Messemaker</surname><given-names>M</given-names></name><etal/></person-group><article-title>CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers</article-title><source>Science</source><year>2023</year><volume>381</volume><issue>6657</issue><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1126/science.ade2292</pub-id><pub-id pub-id-type="pmcid">PMC10755760</pub-id><pub-id pub-id-type="pmid">37535729</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>TRJ</given-names></name><name><surname>Basu</surname><given-names>B</given-names></name><name><surname>Hubner</surname><given-names>R</given-names></name><etal/></person-group><article-title>A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC)</article-title><source>Journal of Clinical Oncology</source><year>2023</year><volume>41</volume><issue>4_suppl</issue><elocation-id>TPS631-TPS631</elocation-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>J</given-names></name><name><surname>Mackey</surname><given-names>JBG</given-names></name><name><surname>Jamieson</surname><given-names>T</given-names></name><etal/></person-group><article-title>CXCR2 inhibition enables NASH-HCC immunotherapy</article-title><source>Gut</source><year>2022</year><volume>71</volume><issue>10</issue><fpage>2093</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-326259</pub-id><pub-id pub-id-type="pmcid">PMC9484388</pub-id><pub-id pub-id-type="pmid">35477863</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramon-Gil</surname><given-names>E</given-names></name><name><surname>Geh</surname><given-names>D</given-names></name><name><surname>Leslie</surname><given-names>J</given-names></name></person-group><article-title>Harnessing neutrophil plasticity for HCC immunotherapy</article-title><source>Essays Biochem</source><year>2023</year><volume>67</volume><issue>6</issue><fpage>941</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1042/EBC20220245</pub-id><pub-id pub-id-type="pmcid">PMC10539947</pub-id><pub-id pub-id-type="pmid">37534829</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banta</surname><given-names>KL</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Chitre</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses</article-title><source>Immunity</source><year>2022</year><volume>55</volume><issue>3</issue><fpage>512</fpage><lpage>526</lpage><elocation-id>e519</elocation-id><pub-id pub-id-type="doi">10.1016/j.immuni.2022.02.005</pub-id><pub-id pub-id-type="pmcid">PMC9287124</pub-id><pub-id pub-id-type="pmid">35263569</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>JH</given-names></name><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Grein</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effective Anti-tumor Response by TIGIT Blockade Associated With FcgammaR Engagement and Myeloid Cell Activation</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>573405</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.573405</pub-id><pub-id pub-id-type="pmcid">PMC7577118</pub-id><pub-id pub-id-type="pmid">33117369</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells</article-title><source>Nature</source><year>2024</year><volume>627</volume><issue>8004</issue><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07121-9</pub-id><pub-id pub-id-type="pmcid">PMC11139643</pub-id><pub-id pub-id-type="pmid">38418879</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><issue>6</issue><pub-id pub-id-type="doi">10.1136/jitc-2023-007068</pub-id><pub-id pub-id-type="pmcid">PMC10314633</pub-id><pub-id pub-id-type="pmid">37344099</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>PPAB001, a novel bispecific antibody against CD47 and CD24, enhances anti-PD-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype</article-title><source>Int Immunopharmacol</source><year>2025</year><volume>144</volume><elocation-id>113740</elocation-id><pub-id pub-id-type="pmid">39622130</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Ashique</surname><given-names>AM</given-names></name><name><surname>Weeks</surname><given-names>S</given-names></name><etal/></person-group><article-title>ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms</article-title><source>Cancer Immunol Res</source><year>2024</year><volume>12</volume><issue>5</issue><fpage>592</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">38393969</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><etal/></person-group><article-title>CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer</article-title><source>Pharmacol Res</source><year>2024</year><volume>202</volume><elocation-id>107126</elocation-id><pub-id pub-id-type="pmid">38432446</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logtenberg</surname><given-names>MEW</given-names></name><name><surname>Jansen</surname><given-names>JHM</given-names></name><name><surname>Raaben</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>4</issue><fpage>612</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0356-z</pub-id><pub-id pub-id-type="pmcid">PMC7025889</pub-id><pub-id pub-id-type="pmid">30833751</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Highlights</title></caption><list list-type="bullet" id="L1"><list-item><p>Primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma, as defined by SITC criteria, is associated with poor clinical outcomes.</p></list-item><list-item><p>Tumour microenvironment profiling reveals an immunosuppressive phenotype characterized by high myeloid infiltration, reduced interferon-γ signalling, and T-cell depletion.</p></list-item><list-item><p>The combination of systemic inflammation and low IFN-γ signature expression strongly predicts primary refractoriness and may inform therapeutic decision-making.</p></list-item></list></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Study overview.</title><p>(<bold>A</bold>) Overview of the three cohorts analysed, comprising 1296, 222 and 423 patients, respectively. (<bold>B</bold>) Sample utilisation from each cohort. (<bold>C-D</bold>) Kaplan-Meier curves of OS in Cohort 1 and Cohorts 2+3, stratified by PRef and Responders. AB, Atezolizumab + Bevacizumab; IMC, Imaging Mass Cytometry; TILs, Tumour-infiltrating lymphocytes; OS, Overall Survival; PRef, Primary Refractoriness.</p></caption><graphic xlink:href="EMS207151-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Decoding the HCC TME of PRef and Responders to Atezolizumab plus Bevacizumab.</title><p>(<bold>A</bold>) Schematic of the machine learning-based TILs quantification. (<bold>B</bold>) TILs counts between PRef and Responders in Cohort 1 and 2. (<bold>C-D</bold>) IMC cartoon and clinical information of the cohort for response, PRef and NLR. (E) Identity HeatMap showing the cell types identified in the HCC TME by IMC. (F-H) IMC Data and representative figures for the comparison of whole Parenchyma, Endothelia, Stroma and Immunity between PRef and Responders. CD, Cluster of Differentiation; TME, Tumour Microenvironment; NLR, Neutrophil to Lymphocyte Ratio; MPO, Myeloperoxidase; TAMs, Tumour-associated macrophages; GzmB, Granzyme B; FoxP3, Forkhead box P3; NK, Natural Killer; PanCK, Pan-Cytokeratin; CAFs, Cancer-associated Fibroblasts; vCAFs, Vascular CAFs; myCAFs, Myofibroblast CAFs; αSMA, Alpha-smooth muscle actin; FAP, Fibroblast Activation Protein.</p></caption><graphic xlink:href="EMS207151-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Immune, stromal and systemic predictors to PRef to Atezolizumab plus Bevacizumab.</title><p>(<bold>A-B</bold>) CD163<sup>Int</sup> TAMs and vCAFs are strongly enriched in PRef. Figure 3B shows the mean difference of every cell type for PRef vs Responders. (<bold>C-D</bold>) PRef patients possess a higher T<sup>Reg</sup> / T<sup>Eff</sup> ratio. (<bold>E-G</bold>) Systemic NLR mimics the intratumour NLR. Figure 3F shows the mean difference of every cell type for NLR High vs NLR Low patients. (<bold>H</bold>) Serum IL-6 expression is higher in PRef than in Responders. (<bold>I</bold>) HCC Patients with high serum IL-6 levels have lower OS and PFS. IL-6, Interleukin 6; PFS, Progression-free survival.</p></caption><graphic xlink:href="EMS207151-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Gene expression profiles of myeloid immunosuppression in PRef.</title><p>Differential gene expression (volcano plot) and biological pathways (GSEA analysis by CAMERA of the contrast model in the Hallmark gene set collection) comparing PRef and responders in Cohort 2 (<bold>A</bold>) and Cohort 3 (<bold>B</bold>). Expression of INFγ, CXCL9:SPP1 ratio, Myeloid:T<sup>Eff</sup> ratio and MDSC:T<sup>Eff</sup> ratio signature plus the respective Kaplan–Meier plots in Cohort 2 stratified by median expression score (<bold>C-F</bold>). Conditional Inference Tree (<bold>G</bold>) and Kaplan-Meier plots for Nodes 3, 4, 6 and 7 (<bold>H</bold>). IFNγ, Interferon γ; CXCL9, C-X-C motif chemokine ligand 9; SPP1, Osteopontin; T<sup>Eff</sup>, T Effector; MDSC, Myeloid Derived Suppressor Cell.</p></caption><graphic xlink:href="EMS207151-f004"/></fig></floats-group></article>